Eli Lilly agreed to acquire Verve Therapeutics for about $1 billion upfront, adding a potential treatment for cardiovascular ...

NEW YORK — (AP) — U.S. stock indexes are drifting lower on Tuesday, while oil prices rise again.

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising ...

Eastern time, the S&P 500 was down 0.3%, the Dow Jones Industrial Average fell 0.2%, and the Nasdaq Composite lost 0.4%.

FacebookTweetPin The prospects of a ceasefire in the Middle East have dimmed after a series of comments by President Donald [ ...

Verve is developing drug candidates for heart disease, including the PCSK9-targeted VERVE-102, a base-editing therapy.

Wall Street’s main indexes slipped on Tuesday as the Israel-Iran conflict entered its fifth day, denting global investor ...

Solar stocks drop sharply as Senate Republicans detail changes to Trump’s tax-and-spending bill that would phase out solar, ...

S&P 500 dips on weak retail sales and Iran conflict fears. Will the Fed’s rate decision and rising oil prices drive more volatility this week?

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verve Therapeutics, Inc. (NASDAQ: VERV) to Eli Lilly and Company is fair to Verve shareholders. Under the terms of ...

Yum Brands named Chief Financial Officer Chris Turner as its next chief executive. Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion Deal would add a potential treatment for ...

Eli Lilly plans to acquire Verve for up to $1.3 billion. Shares of Verve Therapeutics (NASDAQ: VERV) were skyrocketing 75.7% ...